Targeting mitochondria to treat chronic kidney disease linked to uromodulin mutations
Therapeutic Targeting of Mitochondria in Uromodulin-Associated Chronic Kidney Disease
This study is looking at a type of kidney disease caused by certain gene changes, and it's using special technology to create mice that have the same issues as people with this condition, so researchers can learn more about how it harms the kidneys and find new ways to help, especially for veterans who might be more affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Louis VA Medical Center NIH-funded |
| Lab location | 1 site (St. Louis, UNITED STATES) |
| Project ID | NIH-10923602 on NIH RePORTER |
What this research studies
This research focuses on chronic kidney disease associated with uromodulin mutations, which leads to progressive kidney damage. The team is using advanced CRISPR technology to create a mouse model that mimics the most common human mutation, allowing them to study the disease's mechanisms. By investigating how mitochondrial dysfunction contributes to kidney cell death, the researchers aim to identify potential therapeutic targets that could improve kidney health. This work is particularly relevant for understanding the disease in veterans, who may be disproportionately affected.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults with a diagnosis of uromodulin-associated chronic kidney disease or those with genetic variants linked to this condition.
Not a fit: Patients with chronic kidney disease not related to uromodulin mutations are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to targeted therapies that significantly improve kidney function and quality of life for patients with uromodulin-associated chronic kidney disease.
How similar studies have performed: While the approach using CRISPR technology is innovative, similar research targeting mitochondrial dysfunction in kidney diseases has shown promise, indicating potential for success.
Where this research is happening
St. Louis, UNITED STATES
- St. Louis VA Medical Center — St. Louis, United States (Active)
Researchers
- Principal investigator: Chen, Ying Maggie — St. Louis VA Medical Center
- Study coordinator: Chen, Ying Maggie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.